Cargando…

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China

OBJECTIVE: This study aims to estimate the cost-effectiveness of yearly intravenous zoledronic acid treatment versus weekly oral alendronate for postmenopausal osteoporotic women in China. METHODS: We used a Markov microsimulation model to compare the cost-effectiveness of zoledronic acid with alend...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Ruxu, Zhang, Yu, Wu, David Bin-Chia, Liu, Jinyu, Qian, Xinyu, Luo, Nan, Mori, Takahiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203488/ https://www.ncbi.nlm.nih.gov/pubmed/32425768 http://dx.doi.org/10.3389/fphar.2020.00456

Ejemplares similares

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Cost‐Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate‐Alone Strategies in High‐Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide
por: Mori, Takahiro, et al.
Publicado: (2019)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
por: Liu, Jinyu, et al.
Publicado: (2021)

Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review
por: Liu, Jinyu, et al.
Publicado: (2023)

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China
por: You, Ruxu, et al.
Publicado: (2019)

The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy
por: Sewerynek, Ewa, et al.
Publicado: (2013)

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia
por: Karnon, Jonathan, et al.
Publicado: (2016)

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate
por: Al-Bogami, Mohammed M., et al.
Publicado: (2015)

Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients
por: Dalle Carbonare, Luca, et al.
Publicado: (2017)

4D label-free quantitative proteomics analysis to screen potential drug targets of Jiangu Granules treatment for postmenopausal osteoporotic rats
por: Lin, Haiming, et al.
Publicado: (2022)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
por: Tariq, Saba, et al.
Publicado: (2022)

Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report
por: Tian, Yiming, et al.
Publicado: (2016)

Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
por: Everts-Graber, Judith, et al.
Publicado: (2023)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy
por: Mullins, C. Daniel, et al.
Publicado: (2003)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Correction to: Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
por: Everts-Graber, Judith, et al.
Publicado: (2023)

The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells
por: Budzinska, Adrianna, et al.
Publicado: (2023)

Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients
por: Hsu, Tsuen-Wei, et al.
Publicado: (2019)

Identifying therapeutic biomarkers of zoledronic acid by metabolomics
por: Li, Xiang, et al.
Publicado: (2023)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
por: Misof, Barbara M., et al.
Publicado: (2020)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Efficacy and Safety of Weekly Alendronate Plus Vitamin D(3) 5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial
por: Kim, Kwang Joon, et al.
Publicado: (2014)

How zoledronic acid improves osteoporosis by acting on osteoclasts
por: Wang, Biao, et al.
Publicado: (2022)

Oral fibroblasts rescue osteogenic differentiation of mesenchymal stem cells after exposure to Zoledronic acid in a paracrine effect
por: Berg, Tal, et al.
Publicado: (2023)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects
por: Chiu, Wei-Yih, et al.
Publicado: (2018)

Alendronate release from calcium phosphate cement for bone regeneration in osteoporotic conditions
por: van Houdt, Claire I. A., et al.
Publicado: (2018)

The Gradual Release of Alendronate for the Treatment of Critical Bone Defects in Osteoporotic and Control Rats
por: Hedvičáková, Věra, et al.
Publicado: (2023)

Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China
por: Wan, Yuansheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s678n0uahf3tjtniulc4kcdpgm